Wet macular degeneration

This trial is testing an experimental eye gel called BETA-TT8 for people with wet age-related macular degeneration (AMD), a condition that causes rapid vision loss. The gel is applied to the eye up to three times daily for 12 weeks, and standard injections remain available if nee…

Researchers are testing an experimental eye injection called GenSci148 in people with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). GenSci148 is a fusion protein designed to block four proteins involved in blo…

Researchers are testing an experimental drug called OLN324 against ranibizumab, a standard treatment for wet age-related macular degeneration (nAMD). The trial enrolls about 400 adults aged 50 and older who have not yet received treatment for active wet AMD in the study eye. Part…

Researchers are testing an experimental drug called OLN324 against the standard treatment, aflibercept, in adults with wet age-related macular degeneration. About 500 people aged 50 and older who have not yet received treatment for this condition will take part. Both drugs are gi…

This trial tests an experimental drug called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. Researchers compare two doses of VIS-101 against aflibercept, a standard treatment, to see if VIS-…

This study tests whether a low-intensity laser applied to the diseased area just before an anti-VEGF injection helps the drug work better in people with wet age-related macular degeneration (AMD). Wet AMD causes abnormal blood vessels to leak fluid under the retina, and current t…

This study looks at whether switching to a higher-dose eye injection called aflibercept 8 mg can allow people with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DME) to go longer between treatments. It follows adults in Portugal who have already …

This trial is investigating whether a higher 8 mg dose of aflibercept, given every three months, can effectively control wet age-related macular degeneration (nAMD) in people who have not been treated before. The study will measure changes in eye fluid biomarkers, vision, and saf…

This Phase 2a trial tests SCAI-005 eye drops in 50 adults with wet age-related macular degeneration (AMD). Participants will receive either a low dose, high dose, or placebo drops three times daily. The study aims to see if the drops can reduce retinal swelling and control the di…

This study will test the drug faricimab, given as eye injections, in 50 people with wet age-related macular degeneration (nAMD). The goal is to see if it improves vision and eye health. Participants will receive 4 initial doses, then more as needed. The study is observational, me…

This study looks at whether a home monitoring app can help people with wet age-related macular degeneration (eAMD) safely extend the time between Aflibercept injections. About 80 adults already receiving this treatment will use the app and have regular eye exams over one to two y…

This study tests a new medicine called AIV007 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. About 35 participants will receive either AIV007 or the standard treatment Eylea. The goal is to see if AIV007 can improve vision and reduce t…

This study tests an investigational drug called OCUL101 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision and can lead to blindness. OCUL101 targets two proteins involved in the disease to reduce abnormal blood vessel growth and inf…

This phase 3 trial tests whether adding Sanhuang Jingshiming Pills (a traditional Chinese herbal medicine) to standard ranibizumab injections can reduce the number of injections needed for wet age-related macular degeneration. About 450 adults aged 50-85 with active wet AMD will …

This phase 3 trial tests whether a new drug, QL1207H, works as well as the standard treatment Eylea for wet age-related macular degeneration, a leading cause of vision loss. About 356 adults aged 50 and older with active disease will receive injections every 4 weeks for 3 doses, …

This early-stage trial tests a new drug called GB10, given as an eye injection, for people with wet age-related macular degeneration (AMD). The study will include 48 participants and aims to check safety and find the right dose. It is not yet recruiting and is too early to know i…

This study tests a stronger dose (8 mg) of the drug aflibercept in Chinese patients with polypoidal choroidal vasculopathy (PCV), a type of wet age-related macular degeneration that can cause rapid vision loss. About 174 people who have not been treated before will receive three …

This early-stage trial tests EXG202, a gene therapy given as a single injection into the eye for people with wet age-related macular degeneration (AMD). The goal is to see if it is safe and can produce a protein that blocks abnormal blood vessel growth long-term, potentially redu…

This trial tests an artificial intelligence system called QiLin that helps doctors decide when to give anti-VEGF injections for retinal diseases like wet AMD, DME, and RVO. About 200 patients who have completed initial treatment will be randomly assigned to have their doctor use …

This study tests a compact, handheld eye imaging device that takes pictures of the eye in seconds. Researchers want to see if it is easy to use, mobile, and reliable. The device will be tested on 70 people with eye complaints, and the images will be compared to official diagnoses…

This study will test a new, non-invasive eye scanner called wide field OCTA in 200 people with various eye diseases, including age-related macular degeneration, diabetic retinopathy, and dry eye. The goal is to see if this device can provide better images of blood vessels in the …

This study tests if using a cotton-tipped applicator to hold the eyelid open during eye injections is less painful and faster than the standard metal speculum. About 120 adults with certain eye conditions will take part. The goal is to improve comfort and satisfaction without com…

Anti-VEGF injections treat conditions like diabetic macular edema, age-related macular degeneration, and retinal vein occlusion by adding fluid inside the eye, which can briefly raise eye pressure. This observational study at Assiut University follows 50 adults receiving these ro…

Doctors use anti-VEGF injections to treat retinal diseases such as age-related macular degeneration and diabetic macular edema, and patients often need these shots for years. During each injection, a small tool holds the eyelids open, stretching the upper lid. Researchers want to…

This early-stage trial is evaluating the safety, tolerability, and how the body absorbs PAN-90806, an experimental eye drop being developed for wet age-related macular degeneration (AMD), a leading cause of vision loss. Healthy adults aged 18 to 50 will receive either PAN-90806 o…

This study will test a new, noninvasive camera called XyCAM CRE that measures blood flow in the back of the eye. Researchers will compare its images with standard eye tests in 350 adults with retinal disorders. The goal is to see if this camera can provide extra information to he…

This study tests whether a personalized care approach helps patients with chronic macular diseases (like wet age-related macular degeneration and diabetic macular edema) attend their regular eye injection appointments. Many patients skip these vital treatments, risking further vi…

This study aims to see if elderly patients with age-related macular degeneration (AMD) find a new web-based eye-tracking system easy and acceptable to use at home. The system is designed to help patients monitor their vision without frequent clinic visits. Thirty patients aged 55…

This study looks back at medical records of 200 people with inherited retinal diseases, like retinitis pigmentosa and Stargardt disease. Researchers will analyze vision tests and eye scans to see how these diseases progress and how genetics affect symptoms. The goal is to find be…